首页> 外文期刊>Scandinavian journal of rheumatology >Plasma von Willebrand factor, tissue plasminogen activator, plasminogen activator inhibitor, and antithrombin III levels in Behcet's disease.
【24h】

Plasma von Willebrand factor, tissue plasminogen activator, plasminogen activator inhibitor, and antithrombin III levels in Behcet's disease.

机译:Behcet病患者的血浆von Willebrand因子,组织纤溶酶原激活物,纤溶酶原激活物抑制剂和抗凝血酶III水平。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Sixty-three patients with Behcet's disease (BD), 30 patients with recurrent oral ulcer and 30 healthy individuals as control group were included in the study. ISG criteria was used for the diagnosis of BD and patients were classified as active and inactive and evaluated accordingly. In the patient and control groups, von Willebrand factor (vWF), tissue plasminogen activator (tPA), and plasminogen activator inhibitor (PAI) levels were determined using ELISA method and antithrombin III (AT-III) by nephelometric methods. High levels of endothelial product, vWF in the active Behcet patient group (p < 0.005) supports endothelial destruction due to vasculitis related with BD. In the active patient group tPA levels were significantly lower (p < 0.05) than the inactive and control groups with higher levels of PAI (p < 0.05 and p < 0.01) respectively. In Behcet disease, besides the decrease in tPA synthesis, high PAI levels also can affect tPA decrease and lead to inhibition of fibrinolytic activity. In active Behcet group, levels of AT-III were low and no significant difference was observed in recurrent oral ulcer and control groups. This situation may arise from the excessive use of AT-III in active disease. In conclusion, high levels of vWF in Behcet patients is thought to arise from vasculitis and high levels of PAI from the accumulation of thrombocytes on the damaged surface of endothelium leading to a decrease in tPA levels and inhibition of fibrinolytic activity.
机译:本研究纳入了63例白塞病(BD)患者,30例复发性口腔溃疡患者和30例健康个体作为对照组。 ISG标准用于BD的诊断,将患者分为活动型和非活动型,并进行相应评估。在患者和对照组中,通过比浊法使用ELISA方法和抗凝血酶III(AT-III)来测定von Willebrand因子(vWF),组织纤溶酶原激活物(tPA)和纤溶酶原激活物抑制剂(PAI)的水平。活动的Behcet患者组中高水平的内皮产物vWF(p <0.005)支持由于与BD相关的血管炎引起的内皮破坏。在活动患者组中,tPA水平显着低于(P <0.05),与不活动组和对照组相比,PAI分别较高(P <0.05和P <0.01)。在Behcet病中,除了tPA合成减少外,高PAI水平也会影响tPA下降并导致纤溶活性受到抑制。在活跃的Behcet组中,AT-III的水平很低,复发性口腔溃疡组和对照组均未观察到显着差异。这种情况可能是由于在活动性疾病中过量使用AT-III引起的。总之,认为Behcet患者的vWF高水平是由血管炎引起的,而高水平的PAI是由于血小板在内皮受损表面上的积聚导致tPA含量降低和纤溶活性受到抑制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号